Peptide-Major Histocompatibility Complex (pMHC) on autologous dendritic cells (pMHC-DC)

Peptide-Major Histocompatibility Complex (pMHC) on autologous dendritic cells is a fundamental component of the immune synapse required for initiating adaptive immunity. Dendritic cells (DCs), as professional antigen-presenting cells, internalize antigens and process them into short peptides that are loaded onto MHC class I and class II molecules for presentation to CD8+ and CD4+ T cells, respectively (Rock et al., 2016). This target is central to the development of autologous dendritic cell vaccines, where a patient's own DCs are harvested, matured, and loaded with specific antigens ex vivo before being re-administered (Banchereau & Steinman, 1998). The primary therapeutic goal is to trigger a potent, antigen-specific cytotoxic T lymphocyte (CTL) response against tumor cells or pathogens. Sipuleucel-T, the first FDA-approved cellular immunotherapy for prostate cancer, utilizes this mechanism by presenting prostatic acid phosphatase (PAP) peptides to the patient's immune system (Kantoff et al., 2010). The interaction between the pMHC and the T-cell receptor (TCR) provides the first signal for T-cell activation, while co-stimulatory molecules on the DC provide the necessary second signal. Therapeutic strategies often involve enhancing the density of pMHC complexes or the longevity of DC-T cell interactions. Despite their potential, challenges remain in ensuring consistent DC maturation and overcoming the immunosuppressive tumor microenvironment that can inhibit pMHC-mediated T-cell activation. Monitoring the efficacy of these therapies often involves measuring the expansion of antigen-specific T-cell populations. This approach represents a personalized form of immunotherapy tailored to the patient's own immune system and specific disease antigens.

Other names

pMHC complexAntigen-MHC complexHLA-peptide complexDendritic cell-presented antigenpMHC class I/II complex

Ex vivo loading of autologous dendritic cells with specific antigens to present pMHC complexes that activate endogenous T cells upon re-infusion.